File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs

TitleEfficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs
Authors
KeywordsLorcaserin
Meta‐analysis
Treatment outcome
Weight loss
Issue Date2013
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1467-789X
Citation
Obesity Reviews, 2013, v. 14 n. 5, p. 383-392 How to Cite?
AbstractLorcaserin is a new anti‐obesity drug recently approved by US Food and Drug Administration. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the association of lorcaserin therapy with weight loss and adverse events in obese adults (18–65 years old). Weight loss of 3.23 kg (95% confidence interval [CI]: 2.70, 3.75) and body mass index reduction of 1.16 kg m−2 (95% CI: 0.98, 1.34) was observed compared with placebo in RCTs of 1 year duration. The use of lorcaserin for 8 and 12 weeks reduced weight of 1.60 kg (95% CI: 0.34, 2.86) and 2.9 kg (95% CI: 2.2, 3.5), respectively. In comparison to placebo, lorcaserin decreased waist circumference, blood pressure, total cholesterol, low‐density lipoprotein‐cholesterol and triglycerides, however did not statistically affect heart rate or high‐density lipoprotein‐cholesterol. Headache, nausea and dizziness were found to be significantly higher in the patients receiving lorcaserin than patients receiving placebo, whereas diarrhoea is no more likely than in patients receiving placebo. In conclusion, lorcaserin achieves modest weight loss and appears to be well tolerated. Clinical and pharmacovigilance studies with longer study duration are needed to inform of the long‐term efficacy and safety of lorcaserin.
Persistent Identifierhttp://hdl.handle.net/10722/186124
ISSN
2019 Impact Factor: 7.31
2015 SCImago Journal Rankings: 4.277
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, WYE-
dc.contributor.authorHe, Y-
dc.contributor.authorChui, SLC-
dc.contributor.authorWong, YS-
dc.contributor.authorLau, CY-
dc.contributor.authorWong, ICK-
dc.date.accessioned2013-08-20T11:56:19Z-
dc.date.available2013-08-20T11:56:19Z-
dc.date.issued2013-
dc.identifier.citationObesity Reviews, 2013, v. 14 n. 5, p. 383-392-
dc.identifier.issn1467-7881-
dc.identifier.urihttp://hdl.handle.net/10722/186124-
dc.description.abstractLorcaserin is a new anti‐obesity drug recently approved by US Food and Drug Administration. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to evaluate the association of lorcaserin therapy with weight loss and adverse events in obese adults (18–65 years old). Weight loss of 3.23 kg (95% confidence interval [CI]: 2.70, 3.75) and body mass index reduction of 1.16 kg m−2 (95% CI: 0.98, 1.34) was observed compared with placebo in RCTs of 1 year duration. The use of lorcaserin for 8 and 12 weeks reduced weight of 1.60 kg (95% CI: 0.34, 2.86) and 2.9 kg (95% CI: 2.2, 3.5), respectively. In comparison to placebo, lorcaserin decreased waist circumference, blood pressure, total cholesterol, low‐density lipoprotein‐cholesterol and triglycerides, however did not statistically affect heart rate or high‐density lipoprotein‐cholesterol. Headache, nausea and dizziness were found to be significantly higher in the patients receiving lorcaserin than patients receiving placebo, whereas diarrhoea is no more likely than in patients receiving placebo. In conclusion, lorcaserin achieves modest weight loss and appears to be well tolerated. Clinical and pharmacovigilance studies with longer study duration are needed to inform of the long‐term efficacy and safety of lorcaserin.-
dc.languageeng-
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1467-789X-
dc.relation.ispartofObesity Reviews-
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectLorcaserin-
dc.subjectMeta‐analysis-
dc.subjectTreatment outcome-
dc.subjectWeight loss-
dc.titleEfficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs-
dc.typeArticle-
dc.identifier.emailChan, WYE: ewchan@hku.hk-
dc.identifier.emailHe, Y: helenhe@hku.hk-
dc.identifier.emailChui, SLC: cslchui@hku.hk-
dc.identifier.emailWong, YS: angelwys@hku.hk-
dc.identifier.emailLau, CY: wallisy@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityChan, WYE=rp01587-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/obr.12015-
dc.identifier.pmid23331711-
dc.identifier.scopuseid_2-s2.0-84876483004-
dc.identifier.hkuros217226-
dc.identifier.volume14-
dc.identifier.issue5-
dc.identifier.spage383-
dc.identifier.epage392-
dc.identifier.isiWOS:000317984300003-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats